Ménière's Disease

Ménière's disease is an idiopathic disorder of the inner ear whose pathological correlate — first proposed by Prosper Ménière in 1861 and later confirmed histopathologically — is endolymphatic hydrops: an abnormal distension of the endolymph-filled membranous labyrinth, thought to arise from a combination of endolymph overproduction and impaired resorption through the endolymphatic sac. The clinical result is a genuinely distinctive pattern often called the "classic tetrad": recurrent, spontaneous episodes of true rotational vertigo lasting 20 minutes to 12 hours, together with fluctuating low- to medium-frequency sensorineural hearing loss, tinnitus, and a sensation of aural fullness or pressure — all affecting the same ear. The word "fluctuating" is doing real diagnostic work here and is worth emphasizing to every patient and colleague: unlike most other causes of sensorineural hearing loss, which simply worsen over time, Ménière's disease hearing classically comes and goes, at least in its earlier stages, tracking with disease activity rather than declining in a smooth line.

Paired audiograms from the same Ménière's disease patient, 20 months apart, showing the classic low-frequency-predominant sensorineural hearing loss pattern — and, comparing the 2 tracings, the genuine fluctuation in threshold that the diagnostic criteria require to be documented at least once. (Ijustam, public domain, Wikimedia Commons)

Ménière's disease is uncommon but not rare: a large United States health-claims analysis covering more than 60 million patients found an overall prevalence of about 190 per 100,000, rising from roughly 9 per 100,000 under age 18 to about 440 per 100,000 in patients 65 and older, with women affected roughly 1.9 times as often as men.^[1] Onset is most common in the 4th through 6th decades of life. The disease is unilateral at onset in the substantial majority of patients, though a minority go on to develop contralateral involvement over years of follow-up — a possibility worth flagging early, since it materially changes the risk calculus for any ablative treatment considered later (see Special Populations and Treatment Failure/Next Step). The natural history is genuinely variable but has a recognizable overall shape: on average, the vestibular attacks themselves tend to "burn out," with no further vertigo episodes by about 8 years after onset, while the sensorineural hearing loss tends to become progressively more fixed and less reversible over the same period — so a patient whose vertigo has resolved is not necessarily a patient whose hearing has stabilized, and both threads need to be followed independently.^[2] This chapter is deliberately scoped to Ménière's disease itself; for the mechanics of canalithiasis and the Epley/Semont repositioning maneuvers, see the dedicated Benign Paroxysmal Positional Vertigo chapter, and for the general medication-induced and multifactorial dizziness work-up, see the Dizziness chapter.

The 4 components, and why "fluctuating" matters more than "present"

Disease course and presentation variants

Some patients present initially with only fluctuating low-frequency hearing loss and aural fullness, without vertigo — historically termed "cochlear hydrops" — and go on to develop vertigo attacks months to years later; conversely, some never develop the full audiometrically confirmed picture, a scenario the modern diagnostic criteria capture as "probable" rather than "definite" disease (see Assessment & Diagnosis). As the disease progresses, particularly in longstanding or poorly controlled cases, a minority of patients develop Tumarkin otolithic crises ("drop attacks") — a sudden, unprovoked fall to the ground without loss of consciousness or a preceding sensation of vertigo, thought to result from a sudden mechanical deformation of the utricular or saccular otolithic organs. These are genuinely dangerous (fall/injury risk) and carry real occupational and driving-safety implications (see Non-Pharmacologic Treatment and Special Populations).

Diagnostic categories at a glance

Both categories require the pattern to be genuinely recurrent — a single episode, however classic-sounding, is not enough to diagnose Ménière's disease on first presentation.^[3][4]

• Idiopathic in the great majority of cases — no single identifiable cause is found in most patients.
• Age 20s through 60s at onset, with a peak in the 4th to 6th decades of life.
• Female sex — affected roughly 1.9 times as often as men.
• A family history of Ménière's disease — a minority of cases cluster in families, suggesting a genetic contribution in some patients, though no single causative gene has been established for the great majority of cases.
• Autoimmune conditions, particularly autoimmune thyroid disease — an association is recognized, though causation is not established for most patients.
• A personal or family history of migraine, including vestibular migraine — a genuinely important overlap population (see Assessment & Diagnosis).
• A history of allergy has been proposed as a contributing factor in some patients, though the evidence is mixed.
• Head trauma or prior otologic/ear surgery, in a minority of cases.
• Anatomic factors such as a narrow or underdeveloped vestibular aqueduct have been proposed as predisposing in some patients, based on imaging studies.
• Significant psychosocial stress is frequently reported by patients as an attack trigger, though its role in disease causation versus attack triggering specifically is not well separated in the evidence.

History

Characterize each of the 4 tetrad components specifically, not just "dizziness" — episode duration (20 minutes to 12 hours, not seconds and not continuous days), whether hearing, tinnitus, and fullness genuinely fluctuate (better some days, worse others) rather than simply and steadily worsening, and whether all 4 features consistently localize to the same ear. Ask specifically about migraine history and features accompanying the vertigo episodes themselves (headache, photophobia, phonophobia, visual aura) given the substantial overlap with vestibular migraine, and about autoimmune symptoms, recent head trauma or ear surgery, and a family history of Ménière's disease. Screen explicitly for every red flag above, and ask directly about any sudden unexplained falls (possible Tumarkin crises) and about current driving.

Audiometry — obtain in every patient

A pure-tone audiogram is a strong, guideline-level recommendation for every patient being assessed for Ménière's disease, both to help confirm the diagnosis and to establish the baseline needed to track the disease's genuinely fluctuating course over time.^[4] The classic early pattern is low-frequency-predominant sensorineural hearing loss, often producing a "peaked" or "rising" audiogram shape (see the image in Clinical Snapshot); with disease duration the pattern frequently extends to higher frequencies and flattens. A single audiogram cannot establish fluctuation on its own — serial audiograms over time are what confirm the pattern the diagnostic criteria require (see Monitoring & Follow-Up).

Imaging — targeted, not routine

Routine MRI is not required to diagnose typical Ménière's disease, but the guideline explicitly allows offering MRI of the internal auditory canals and posterior fossa with gadolinium, particularly to exclude vestibular schwannoma or another retrocochlear cause — this becomes considerably more important, not optional, when hearing loss is asymmetric, progressive rather than fluctuating, or otherwise atypical.^[4] Delayed-enhancement inner-ear MRI protocols that directly visualize endolymphatic hydrops itself are an active area of research at some tertiary centres but are not yet a routine standard-of-care diagnostic step, and are not required to make the clinical diagnosis.

Vestibular and electrophysiologic testing — not required to establish the diagnosis

Formal vestibular function testing (electronystagmography/videonystagmography) or electrocochleography should not be routinely ordered to establish a Ménière's disease diagnosis in a patient who meets the clinical and audiometric criteria above.^[4] These tests retain a role in the hands of a vestibular specialist for atypical, equivocal, or refractory presentations, but are not a required or first-line diagnostic step.

Differential diagnosis

• Confirm the diagnosis efficiently with history, tetrad characterization, and audiometry, applying the definite/probable criteria rather than diagnosing from a single episode.
• Identify and appropriately refer the patient whose presentation is actually a mimic — vestibular migraine, vestibular schwannoma, autoimmune inner ear disease, superior canal dehiscence, or a central cause.
• Educate every patient honestly about the genuinely variable, fluctuating natural history, including that vertigo attacks tend to lessen over years while hearing loss tends to become more fixed — 2 threads that need to be tracked and discussed separately.
• Reduce vertigo attack frequency and severity through a stepwise approach, starting with the lowest-risk, lowest-cost interventions.
• Preserve hearing and vestibular function as long as possible, weighing this explicitly before any ablative escalation, especially in bilateral disease or the only hearing ear.
• Manage acute attacks symptomatically without allowing vestibular suppressant use to drift into chronic, maintenance-style therapy.
• Present the evidence for betahistine and diuretic maintenance therapy honestly, including its real limitations, rather than promising an effect the trial evidence does not clearly support.
• Address the genuine psychosocial burden of an unpredictable episodic condition, and provide concrete safety counselling — particularly driving safety — proactively rather than only after an incident.
• Escalate to intratympanic and surgical therapy only after an adequate, honestly-assessed trial of lower-risk measures, and choose the specific escalation option based on laterality and how much preserving hearing matters for that patient.

Acute vertigo attacks

Attack-limited use only a vestibular suppressant or antiemetic — dimenhydrinate, prochlorperazine, ondansetron, or, for a severe attack, a short-acting benzodiazepine — may be offered strictly during the attack itself.^[4] Do not continue these agents into the interattack period as a default maintenance strategy — as in BPPV and general dizziness management, chronic vestibular-suppressant use does not treat the underlying hydrops and can blunt the central compensation process, on top of each individual drug's own sedation, anticholinergic, or dependence risk.

Dietary and lifestyle modification

1st-line maintenance measure, every patient sodium restriction, along with reducing caffeine, alcohol, and monosodium glutamate intake and general stress reduction (see Non-Pharmacologic Treatment for the specific, practical targets).^[4][2] This recommendation carries genuine, guideline-level backing for patient education, even though the supporting trial evidence for dietary modification specifically is not high-quality RCT evidence — its low cost and low risk make it a reasonable universal first step regardless.

Oral maintenance pharmacotherapy — an honest picture

Option, individualized trial betahistine and/or a diuretic (typically triamterene/hydrochlorothiazide) may be offered for maintenance therapy to reduce or prevent attacks.^[4] The evidence for both is genuinely limited: the BEMED trial, a rigorous multicentre, double-blind, placebo-controlled, dose-defining RCT, found that betahistine — even at a high dose (3 times 48 mg daily) well above the standard label dose — did not significantly reduce the number of vertigo attacks compared with placebo over 9 months of follow-up.^[7] The 2023 Cochrane review of systemic pharmacological interventions for Ménière's disease similarly found only low-certainty evidence across betahistine, diuretics, and other systemic agents.^[8] None of this means these drugs are useless for a given individual patient — the trial designs used may not capture every real-world benefit, and both remain widely prescribed given their low risk profile — but patients deserve this honest framing rather than an overstated promise of efficacy, particularly since betahistine is genuinely Canada's approved, on-label indication for exactly this use (per the Health Canada SERC monograph) while it is not FDA-approved in the United States at all — a real access point worth knowing when counselling a patient who has spent time in, or gets prescriptions filled in, the US.^[9]

What the guideline explicitly says not to do

Do not prescribe positive pressure therapy (a device such as the Meniett, applying pulsed pressure to the middle ear via a ventilation tube) — the guideline is explicit that this should not be offered, reflecting insufficient supporting evidence despite the device's continued marketing and availability.^[4]

Dietary and lifestyle modification, in practical terms

• Sodium restriction — the Canadian Family Physician review's specific, practical target is not to exceed 2,300 mg of sodium per day, matching general Canadian dietary guidance; counsel patients concretely (reading nutrition labels, limiting processed and restaurant food, not just "avoiding the salt shaker") and consider a dietitian referral for patients who struggle with adherence.^[2]
• Caffeine and alcohol reduction — both are commonly reported attack triggers; a trial reduction is reasonable and low-risk.
• Limit monosodium glutamate (MSG) intake, alongside general sodium restriction.^[2]
• Stress reduction — genuinely reported by many patients as an attack trigger; simple stress-management counselling is a reasonable, low-risk adjunct.^[2]
• Maintain consistent hydration rather than large day-to-day swings in fluid intake.

What the evidence explicitly does not support

Do not offer positive pressure therapy — reflecting the same guideline "should not" statement discussed in Choose Initial Treatment.^[4]

Vestibular rehabilitation — for interattack imbalance, not for the attack itself

Reasonable, guideline-recommended vestibular rehabilitation/physical therapy for patients with chronic imbalance between attacks.^[4] Do not recommend vestibular rehabilitation for managing an acute vertigo attack itself — it is not designed for, and will not help with, the acute episode.^[4]

Hearing preservation and amplification

Counsel every patient with documented hearing loss on amplification and hearing-assistive technology (hearing aids, assistive listening devices) as part of routine care, not only once vertigo itself is well controlled — hearing loss in Ménière's disease often persists and progresses independently of vertigo control (see Monitoring & Follow-Up).^[4]

Psychosocial support and safety counselling

• Acknowledge explicitly that unpredictable, spontaneous vertigo attacks are genuinely anxiety-provoking and disruptive to work and social life — this is not a minor complaint, and proactive psychosocial support (counselling, a vestibular-disorder patient support organization) is a reasonable part of comprehensive care, not an afterthought.
• Driving safety — most patients can continue driving if they experience reliable warning symptoms (aural fullness, tinnitus change) before an attack that would allow them to safely pull over; a patient who has experienced a Tumarkin drop attack, or any attack without adequate warning, needs an urgent, explicit conversation about driving restriction until reassessed and stable (a commonly cited benchmark is roughly 6 months attack-free, though exact requirements are set by the relevant provincial licensing authority and should be confirmed rather than assumed).^[2]
• Counsel on avoiding unsupervised activities with significant fall or injury consequences during a period of active, unpredictable disease — climbing ladders, working at heights, swimming alone — particularly after any drop attack.

Older adults

Vertigo attacks and Tumarkin drop attacks both carry disproportionate fall/injury consequences in older adults, and this risk compounds with any diuretic's own orthostatic effect (cross-reference the Dizziness chapter's orthostatic-hypotension mechanism) and with any sedating vestibular suppressant used during an attack. Preferred approach proactive fall-risk counselling and periodic electrolyte/renal monitoring for a patient on maintenance diuretic therapy; hearing loss also compounds social isolation risk in this group, making proactive amplification counselling particularly worthwhile.

Pregnancy

Data on Ménière's disease treatment in pregnancy are limited. Per the Health Canada product monograph, betahistine's safety in human pregnancy has not been established, and animal reproduction data are insufficient — it should not be used during pregnancy unless the potential benefit to the mother outweighs the potential risk to the fetus.^[9] Thiazide-based diuretics are generally avoided for a non-obstetric indication in pregnancy given limited safety data for this use; confirm any medication decision against the specific drug's own Drug Database entry and involve obstetrics. For an acute attack, dimenhydrinate is a reasonable and commonly used option in pregnancy, consistent with the approach in the BPPV chapter; avoid benzodiazepines where possible.

Breastfeeding

Per the Health Canada monograph, it is unknown whether betahistine is excreted into human milk, though it accumulates in the milk of lactating rat dams — weigh the importance of the drug to the mother against the potential risk to the infant, and confirm specifics against the drug's own Drug Database entry.^[9] Dimenhydrinate and ondansetron are both generally considered reasonable at standard short-term doses for an acute attack; confirm against each drug's own entry.

Pediatrics

Ménière's disease is rare in children; vestibular migraine is a substantially more common cause of episodic vertigo in this age group and should be the leading consideration before Ménière's disease. Per the Health Canada monograph, betahistine is not recommended under 18 years of age given insufficient safety and efficacy data.^[9] When Ménière's disease is genuinely suspected in a child, involve pediatric otolaryngology.

Hepatic impairment

Betahistine is highly hepatically metabolized, and the Health Canada monograph states no pharmacokinetic data exist in hepatic impairment — use with caution in this population.^[9]

Renal impairment

Diuretic dosing and electrolyte monitoring need particular attention. Intratympanic gentamicin has minimal systemic absorption, so systemic nephrotoxicity risk is low but not zero — confirm monitoring specifics with the administering otolaryngologist.

Bilateral Ménière's disease, or disease in the only hearing ear

This is a critical branch point rather than a minor detail. Any ablative escalation — intratympanic gentamicin, labyrinthectomy, vestibular nerve section — deliberately destroys vestibular (and, for labyrinthectomy, cochlear) function on the treated side, an acceptable trade-off only when the contralateral ear has adequate compensatory vestibular function and, ideally, useful hearing of its own. In bilateral disease or when the affected ear is the patient's only hearing ear, intratympanic corticosteroid and endolymphatic sac surgery are the preferred escalation routes precisely because they do not carry the same deliberate ablative risk (see Treatment Failure/Next Step).

Peptic ulcer disease and asthma

Betahistine is contraindicated in active or prior peptic ulcer disease and in hypersensitivity to the drug, and requires caution in asthma given rare reports of clinical intolerance in asthmatic patients — per the Health Canada monograph.^[9]

Reassess within weeks to a few months of starting any new maintenance measure (dietary modification, betahistine, and/or a diuretic) — confirm dietary adherence specifically rather than assuming it, review a symptom diary for attack frequency, duration, and severity, and check electrolytes and renal function if a diuretic was started.

• Obtain serial audiograms at a regular interval rather than a single baseline test — a single audiogram cannot demonstrate the fluctuation the diagnostic criteria require, and hearing in Ménière's disease characteristically declines in a stepwise rather than smooth pattern, so periodic reassessment is what actually tracks the real trajectory.
• Reassess for vestibular migraine overlap or an evolving alternate diagnosis if the pattern changes meaningfully from the original presentation.
• Screen for psychosocial impact and anxiety at follow-up, given how genuinely disruptive an unpredictable episodic condition can be; a validated functional tool such as the Dizziness Handicap Inventory is a reasonable, optional adjunct where available.
• Revisit driving-safety status explicitly after any new drop attack or any attack occurring without adequate warning symptoms.
• Set realistic expectations for the long arc of the disease: vertigo attacks tend, on average, to resolve by about 8 years from onset, but hearing loss tends to become progressively more fixed over the same period — track and discuss both threads, not just whichever one prompted the most recent visit.^[2]
• Revisit amplification and hearing-assistive-technology counselling at follow-up for any patient with documented hearing loss, regardless of how well vertigo itself is currently controlled.

1. Before escalating, reconfirm the diagnosis rather than assuming failure of an otherwise-correct plan — reassess for vestibular migraine overlap, and obtain MRI of the internal auditory canals/posterior fossa if not already done, particularly if hearing loss has become progressive and asymmetric rather than genuinely fluctuating.
2. Confirm an adequate trial of dietary modification, together with oral maintenance pharmacotherapy if used, was actually completed — typically several months — before labelling it a true failure, given the honestly modest and inconsistent effect size already discussed in Choose Initial Treatment.
3. For continued active, disabling vertigo despite an adequate conservative trial, escalate to intratympanic corticosteroid first — a reasonable initial invasive step with materially lower hearing-loss risk than gentamicin, and the preferred choice specifically when hearing preservation matters (bilateral disease, the only hearing ear, or patient preference).^[4]
4. If intratympanic corticosteroid does not adequately control vertigo and the disease is unilateral with an adequately hearing contralateral ear, intratympanic gentamicin is the guideline-recommended next step — a head-to-head RCT found gentamicin produced vertigo-attack reductions at least comparable to intratympanic methylprednisolone, at the cost of a real, dose-related risk of further hearing loss on the treated side that requires audiometric monitoring between injections.^[4][10]
5. For vertigo remaining disabling despite intratympanic gentamicin, or when gentamicin is not appropriate at all (bilateral disease, or the only hearing ear where any further hearing risk is unacceptable), refer for surgical evaluation: endolymphatic sac decompression/shunt (less destructive, but with more modest and inconsistent supporting evidence), vestibular nerve section (hearing-preserving but a more invasive neurosurgical approach, generally reserved for a good-hearing ear refractory to gentamicin), or labyrinthectomy (a definitive ablative option appropriate only for unilateral disease in an ear that already has poor or no useful hearing).
6. For chronic imbalance persisting once vertigo attacks themselves are controlled, refer for vestibular rehabilitation rather than escalating pharmacologic or surgical vertigo-specific therapy further.
7. Reassess hearing trajectory independently of vertigo control at every escalation step, and revisit amplification/hearing-assistive-technology counselling regardless of how well vertigo is controlled at that point.

• Diagnosing Ménière's disease from a single vertigo episode, rather than requiring ≥2 episodes each meeting the 20-minute-to-12-hour duration criterion.
• Not obtaining an audiogram — the single objective test that most helps confirm the diagnosis and separate it from several of its mimics.
• Treating progressive, non-fluctuating, asymmetric sensorineural hearing loss as routine Ménière's disease rather than considering vestibular schwannoma and ordering MRI of the internal auditory canals.
• Missing vestibular migraine as a comorbidity or as the actual diagnosis, given how common the overlap genuinely is.
• Continuing a vestibular suppressant (dimenhydrinate, prochlorperazine, a benzodiazepine) as ongoing maintenance therapy rather than limiting it strictly to acute attacks.
• Overstating betahistine's evidence base to patients rather than disclosing the BEMED trial and Cochrane review's honest uncertainty — an individualized trial is reasonable, a guaranteed effect is not.
• Recommending or continuing positive pressure therapy despite the guideline's explicit "should not" statement.
• Proceeding to intratympanic gentamicin or a surgical ablative procedure in bilateral disease or in the only hearing ear without first exhausting non-ablative escalation options.
• Not asking directly about sudden unexplained falls (Tumarkin otolithic crises) and not addressing driving safety proactively, particularly after a first drop attack.
• Framing the condition purely as a "vertigo problem" and neglecting the hearing-preservation, amplification, tinnitus, and psychosocial dimensions of care.
• Not rechecking electrolytes and renal function periodically in a patient on maintenance diuretic therapy.

How to use this table: doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page. Maintenance pharmacotherapy is an individualized trial with genuinely mixed evidence, not a guaranteed-effective therapy — see Choose Initial Treatment for the honest evidence discussion.

Maintenance Oral Pharmacotherapy — Option-Level Evidence

Offered as an individualized trial to reduce or prevent attacks, not as a guaranteed-effective therapy — disclose the genuinely mixed trial evidence (BEMED trial, 2023 Cochrane review) honestly to the patient.

Acute Attack — Vestibular Suppressants and Antiemetics (Brief, Attack-Limited Use Only)

Reserve strictly for the duration of an acute vertigo attack. Stop as soon as the attack resolves — continued use does not treat the underlying hydrops and can impair the central nervous system's own compensation, exactly as in the BPPV and Dizziness chapters.

Intratympanic Escalation Therapy — Administered by Otolaryngology

For active disease not adequately controlled by dietary modification and oral maintenance pharmacotherapy. Choice between the 2 agents below depends heavily on laterality and how much preserving hearing matters for that specific patient (see Treatment Failure/Next Step and Special Populations).